

---

## Fluoguide Q2 2024 - Following the plan

Redeye comments on Fluoguide's Q2 2024 report, following its recent cSEK60m directed share issue that came at shareholder-friendly terms. We will closely watch FG001's progression in clinical development and business development news in coming quarters. We do some housekeeping in our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Fluoguide Q2 2024 - Following the plan](#)